AI combining contrast-enhanced and non-contrast CT accurately identifies brain metastases

Deep learning can more accurately distinguish early brain metastases when using both contrast-enhanced and non-contrast CT scans, according to new research published in the European Journal of Radiology.

Researchers designed a model capable of automatically detecting the spread of brain cancer by combining contrast-enhanced and non-contrast imaging, comparing it to models that only use contrast scans. The retrospective study included 116 CTs of 116 patients, all of whom underwent brain scans with and without contrast and had confirmed brain metastases

A total of 659 metastases were present—428 were used for training and validation, and 231 for testing. When the deep learning model was applied, the combined contrast and non-contrast exams produced a higher positive predictive value compared to contrast-only exams (44% versus 37.2%). The results of the study also showed a higher sensitivity rate and decreased number of false positives with the use of both scans.

“The information on true contrast enhancement through comparison of contrast-enhanced and non-enhanced images may improve the performance of the deep learning object detection model and suppress false positives by preventing the detection of pseudolesions as brain metastases,” Hidemasa Takao, MD, PhD, with the Department of Radiology, Graduate School of Medicine at the University of Tokyo, and co-authors noted. 

Patient outcomes after the discovery of brain metastasis can be abysmal, but earlier detection can result in earlier treatment and a better overall prognosis. The authors suggest their results could benefit these patients by discovering the spread of their cancer sooner and expediting their treatment accordingly. 

You can read the detailed study in the European Journal of Radiology.

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

HeartFlow kicked off TCT 2024 by sharing new research on the long-term impact of its FFRCT Analysis and Plaque Analysis software.

Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.

Trimed Popup
Trimed Popup